BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wu JL, Luo JY, Jiang ZB, Huang SB, Chen GR, Ran HY, Liang QY, Huang MS, Lai LS, Chen JW. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World J Gastroenterol 2023; 29(20): 3168-3184 [PMID: 37346152 DOI: 10.3748/wjg.v29.i20.3168]
URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3168.htm
Number Citing Articles
1
Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Wei Kang. Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studiesClinical and Experimental Medicine 2026; 26(1) doi: 10.1007/s10238-026-02163-x
2
Wong Hoi She, Tan To Cheung. Options and survival benefits of conversion therapy for unresectable hepatocellular carcinomaWorld Journal of Gastroenterology 2024; 30(18): 2479-2481 doi: 10.3748/wjg.v30.i18.2479
3
Cheng Xu, Zhihong Tang, Meng Wei, Danxi Liu, Qingqing Pang, Baishan Huang, Xinglin Mo, Feixiang Wu. Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapyFrontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1602327
4
Xiaojian He, Xu Peng, Jianliang Duan, Zongyang Li, Yuexiang Niu, Yahui Liu. A preoperative inflammatory score-based nomogram predicts overall survival after curative hepatectomy for hepatocellular carcinomaDiscover Oncology 2025; 16(1) doi: 10.1007/s12672-025-03406-1
5
Wenhui Zhang, Jinchuan Shi, Shourong Liu, Er Li, Yan Zhang, Ying Wang, Dingyan Yan, Jianhua Yu, Yi Wang. Development and internal validation of a risk model for hyperuricemia among people living with HIV in Hangzhou, China: a retrospective longitudinal cohort studyFrontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1736775
6
Yinghan Chen, Caiyun Lu, Yucheng Xu, Zhidong Zang. Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCCAlimentary Pharmacology & Therapeutics 2026;  doi: 10.1111/apt.70686
7
Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang. Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023Hepatology International 2026;  doi: 10.1007/s12072-026-11120-5